Key result
Novel lipid-lowering and glucose-controlling agents suggest strong cardiovascular and native CAD benefits after CABG.
Why the study?
Patients undergoing CABG remain at risk for recurrent adverse ischemic events and other cardiovascular outcomes, motivating a summary of recent evidence in pharmacological preventive therapies addressing this residual risk.
Do novel pharmacological preventive therapies improve cardiovascular outcomes in patients who have undergone CABG?
Do novel pharmacological preventive therapies improve cardiovascular outcomes in patients who have undergone CABG?
Novel pharmacological therapies targeting inflammatory, metabolic, and prothrombotic pathways show promise for secondary prevention and improving cardiovascular outcomes after CABG.
May support novel agents in post-CABG care; leaves open dedicated RCTs for graft patency and outcomes.
PURPOSE OF REVIEW: Coronary artery bypass graft (CABG) surgery remains the gold-standard treatment for multivessel and left main coronary artery disease. Despite significant improvement in cardiovascular outcomes, patients undergoing CABG remain at risk for recurrent adverse ischemic events and other cardiovascular outcomes (coronary revascularisation, stroke, cardiac death, etc.). The purpose of this review is to summarize the most recent evidence in pharmacological preventive therapies addressing the residual cardiovascular risk in patients who have undergone CABG. RECENT FINDINGS: Novel cardiovascular pharmacological preventive strategies targeting inflammatory, metabolic and prothrombotic (antiplatelet and anticoagulation) pathways have been recently assessed, with promising results for secondary prevention after CABG. SUMMARY: Secondary prevention is an essential part of postoperative care after CABG. Novel lipid-lowering and glucose-controlling agents suggest a strong and consistent benefit on native coronary artery disease and overall cardiovascular outcomes. The role and the choice of enhanced antiplatelet/anticoagulation/lipid/glucose-modulating therapies following CABG should be better defined and deserves further investigation. Additional studies are required to identify new therapeutic target addressing the specific multifactorial nature of the graft CV disease and identifying the best preventive strategies for long-term graft patency.
No takes yet. Share an insight, caveat, or question.
Paquin et al. (2020) conducted a review in Multivessel and left main coronary artery disease post-CABG. Pharmacological preventive therapies (lipid-lowering, glucose-controlling, antiplatelet, anticoagulation) was evaluated. Novel lipid-lowering and glucose-controlling agents suggest a strong and consistent benefit on native coronary artery disease and overall cardiovascular outcomes after CABG.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: